Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer

S. A. Laurie, S. Banerji, N. Blais, S. Brule, P. K. Cheema, P. Cheung, N. Daaboul, D. Hao, V. Hirsh, R. Juergens, J. Laskin, N. Leighl, R. MacRae, G. Nicholas, D. Roberge, J. Rothenstein, D. J. Stewart, M. S. Tsao


Background Little evidence has been generated for how best to manage patients with non-small-cell lung cancer (nsclc) presenting with rarer clinical scenarios, including oligometastases, oligoprogression, and pseudoprogression. In each of those scenarios, oncologists have to consider how best to balance efficacy with quality of life, while maximizing the duration of each line of therapy and ensuring that patients are still eligible for later options, including clinical trial enrolment.

Methods An expert panel was convened to define the clinical questions. Using case-based presentations, consensus practice recommendations for each clinical scenario were generated through focused, evidencebased discussions.

Results Treatment strategies and best-practice or consensus recommendations are presented, with areas of consensus and areas of uncertainty identified.

Conclusions In each situation, treatment has to be tailored to suit the individual patient, but with the intent of extending and maximizing the use of each line of treatment, while keeping treatment options in reserve for later lines of therapy. Patient participation in clinical trials examining these issues should be encouraged.


Non-small-cell lung cancer; advanced; nsclc; advanced; oligometastatic disease; oligoprogression; pseudoprogression

Full Text:



Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)